

Special Issue

Heart Failure: Personalized Diagnosis, Treatment and Management

Message from the Guest Editor

Heart failure (HF) represents a global health challenge, with rising prevalence and significant morbidity and mortality. Despite advances in pharmacologic and device-based therapies, clinical outcomes remain suboptimal for many patients. The growing recognition of HF as a heterogeneous syndrome—encompassing diverse phenotypes, etiologies, and trajectories—has catalyzed a shift toward personalized medicine. This Special Issue aims to explore emerging strategies for individualized diagnosis, treatment, and long-term management of HF. Ranging from novel biomarkers and imaging modalities to genomics, artificial intelligence, and tailored therapeutics, precision cardiology is reshaping the heart failure landscape. By integrating patient-specific data across biological, clinical, and lifestyle domains, we aim to improve prognostication, optimize therapeutic responses, and enhance quality of life. We welcome scholars to submit reviews and original research articles related to heart failure and personalized medicine.

Guest Editor

Dr. Edgardo J. Kaplinsky

Cardiology Unit, Medicine Department, Hospital Municipal de Badalona, 08911 Badalona, Spain

Deadline for manuscript submissions

31 May 2026



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/248465

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).